Oncolysis of canine tumor cells by myxoma virus lacking the serp2 gene

American Journal of Veterinary Research

Volumn 73, Issue 8, 2012, Pages 1252-1261

  Urbasic, Ashlee S ^a   Hynes, Stacy ^a   Somrak, Amy ^a   Contakos, Stacey ^a   Rahman, Masmudur M ^b   Liu, Jia ^b   MacNeill, Amy L ^a  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b UNIVERSITY OF FLORIDA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROTEIN KINASE B;

ANGIOSARCOMA; ANIMAL CELL; ANIMAL TISSUE; APOPTOSIS; ARTICLE; CADAVER; CELL DEATH; CONNECTIVE TISSUE; CYTOPATHOGENIC EFFECT; DOG; GASTROINTESTINAL STROMAL TUMOR; GENE; HUMAN; HUMAN CELL; KIDNEY CARCINOMA; MASTOCYTOMA; MONOLAYER CULTURE; MYXOMA VIRUS; NONHUMAN; POXVIRUS INFECTION; SERP2 GENE; SOFT TISSUE SARCOMA; TUMOR CELL; UPREGULATION; VIRUS REPLICATION; WILD TYPE;

ANIMALS; APOPTOSIS; BLOTTING, WESTERN; CELL DEATH; CELL LINE, TUMOR; DOG DISEASES; DOGS; GENE DELETION; HUMANS; MICROSCOPY, ELECTRON, TRANSMISSION; MYXOMA VIRUS; NEOPLASMS; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-AKT; RABBITS; VIRAL PROTEINS;

CANIS FAMILIARIS; MYXOMA VIRUS;

EID: 84865618499     PISSN: 00029645     EISSN: None     Source Type: Journal    
DOI: 10.2460/ajvr.73.8.1252     Document Type: Article

References (43)

1. Stojdl DF, Lichty B, Knowles S, et al. Exploiting tumor-specific defects in the interferon pathway with a previously unknown oncolytic virus. Nat Med 2000;6:821-825.
2. Cahill DP, Kinzler KW, Vogelstein B, et al. Genetic instability and darwinian selection in tumours. Trends Cell Biol 1999;9:M57-M60.
3. Vaha-Koskela MJ, Heikkila JE, Hinkkanen AE. Oncolytic viruses in cancer therapy. Cancer Lett 2007;254:178-216.
4. Jiang BH, Liu LZ. PI3K/PTEN signaling in angiogenesis and tumorigenesis. Adv Cancer Res 2009;102:19-65.
5. Soares JA, Leite FG, Andrade LG, et al. Activation of the PI3K/Akt pathway early during vaccinia and cowpox virus infections is required for both host survival and viral replication. J Virol 2009;83:6883-6899.
6. Ricketts CR. Molecular permeability of the burned area. Proc Soc Exp Biol Med 1966;121:770-772.
7. McCart JA, Ward JM, Lee J, et al. Systemic cancer therapy with a tumor-selective vaccinia virus mutant lacking thymidine kinase and vaccinia growth factor genes. Cancer Res 2001;61:8751-8757.
8. Thorne SH, Bartlett DL, Kirn DH. The use of oncolytic vaccinia viruses in the treatment of cancer: a new role for an old ally? Curr Gene Ther 2005;5:429-443.
9. Merchlinsky M, Eckert D, Smith E, et al. Construction and characterization of vaccinia direct ligation vectors. Virology 1997;238:444-451.
10. Karupiah G, Blanden RV. Anti-asialo-GM1 inhibits vaccinia virus infection of murine ovaries: asialo-GM1 as an additional virus receptor? Immunol Cell Biol 1990;68:343-346.
11. Selin LK, Santolucito PA, Pinto AK, et al. Innate immunity to viruses: control of vaccinia virus infection by gamma delta T cells. J Immunol 2001;166:6784-6794.
12. Xu R, Johnson AJ, Liggitt D, et al. Cellular and humoral immunity against vaccinia virus infection of mice. J Immunol 2004;172:6265-6271.
13. Chaudhri G, Panchanathan V, Bluethmann H, et al. Obligatory requirement for antibody in recovery from a primary poxvirus infection. J Virol 2006;80:6339-6344.
14. Fenner F, Woodroffe GM. The pathogenesis of infectious myxomatosis: the mechanism of infection and the immunological response in the European rabbit (Oryctolagus cuniculus). Br J Exp Pathol 1953;34:400-411.
15. Andrewes CH, Harisijades S. Propagation of myxoma virus in one-day old mice. Br J Exp Pathol 1955;36:18-21.
16. Jackson EW, Dorn CR, Saito JK, et al. Absence of serological evidence of myxoma virus infection in humans exposed during an outbreak of myxomatosis. Nature 1966;211:313-314.
17. Gorski J, Mizak B, Chrobocinska M. Control of rabbit myxomatosis in Poland. Rev Sci Tech 1994;13:869-879.
18. Fenner F. Adventures with poxviruses of vertebrates. FEMS Microbiol Rev 2000;24:123-133.
19. McCabe VJ, Tarpey I, Spibey N. Vaccination of cats with an attenuated recombinant myxoma virus expressing feline calicivirus capsid protein. Vaccine 2002;20:2454-2462.
20. McCabe VJ, Spibey N. Potential for broad-spectrum protection against feline calicivirus using an attenuated myxoma virus expressing a chimeric FCV capsid protein. Vaccine 2005;23:5380-5388.
21. Pignolet B, Boullier S, Gelfi J, et al. Safety and immunogenicity of myxoma virus as a new viral vector for small ruminants. J Gen Virol 2008;89:1371-1379.
22. Sypula J, Wang F, Ma Y, et al. Myxoma virus tropism in human tumor cells. Gene Ther Mol Biol 2004;8:103-114.
23. Lun X, Yang W, Alain T, et al. Myxoma virus is a novel oncolytic virus with significant antitumor activity against experimental human gliomas. Cancer Res 2005;65:9982-9990.
24. Lun XQ, Zhou H, Alain T, et al. Targeting human medulloblastoma: oncolytic virotherapy with myxoma virus is enhanced by rapamycin. Cancer Res 2007;67:8818-8827.
25. Stanford MM, Shaban M, Barrett JW, et al. Myxoma virus oncolysis of primary and metastatic B16F10 mouse tumors in vivo. Mol Ther 2008;16:52-59.
26. Lun X, Alain T, Zemp FJ, et al. Myxoma virus virotherapy for glioma in immunocompetent animal models: optimizing administration routes and synergy with rapamycin. Cancer Res 2010;70:598-608.
27. Guo ZS, Naik A, O'Malley ME, et al. The enhanced tumor selectivity of an oncolytic vaccinia lacking the host range and antiapoptosis genes SPI-1 and SPI-2. Cancer Res 2005;65:9991-9998.
28. Messud-Petit F, Gelfi J, Delverdier M, et al. Serp2, an inhibitor of the interleukin-1beta-converting enzyme, is critical in the pathobiology of myxoma virus. J Virol 1998;72:7830-7839.
29. MacNeill AL, Turner PC, Moyer RW. Mutation of the Myxoma virus SERP2 P1-site to prevent proteinase inhibition causes apoptosis in cultured RK-13 cells and attenuates disease in rabbits, but mutation to alter specificity causes apoptosis without reducing virulence. Virology 2006;356:12-22.
30. Nathaniel R, MacNeill AL, Wang YX, et al. Cowpox virus crmA, myxoma virus serp2 and baculovirus P35 are not functionally interchangeable caspase inhibitors in poxvirus infections. J Gen Virol 2004;85:1267-1278.
31. Johnston JB, Barrett JW, Chang W, et al. Role of the serinethreonine kinase PAK-1 in myxoma virus replication. J Virol 2003;77:5877-5888.
32. Liu J, Wennier S, Reinhard M, et al. Myxoma virus expressing interleukin-15 fails to cause lethal myxomatosis in European rabbits. J Virol 2009;83:5933-5938.
33. Duteyrat JL, Gelfi J, Bertagnoli S. Ultrastructural study of myxoma virus morphogenesis. Arch Virol 2006;151:2161-2180.
34. Barrett JW, Alston LR, Wang F, et al. Identification of host range mutants of myxoma virus with altered oncolytic potential in human glioma cells. J Neurovirol 2007;13:549-560.
35. Wang G, Barrett JW, Stanford M, et al. Infection of human cancer cells with myxoma virus requires Akt activation via interaction with a viral ankyrin-repeat host range factor. Proc Natl Acad Sci U S A 2006;103:4640-4645.
36. Kylarova D, Prochazkova J, Mad'arova J, et al. Comparison of the TUNEL, lamin B and annexin V methods for the detection of apoptosis by flow cytometry. Acta Histochem 2002;104:367-370.
37. Porrello A, Cardelli P, Spugnini EP. Oncology of companion animals as a model for humans. an overview of tumor histotypes 2. J Exp Clin Cancer Res 2006;25:97-105.
38. Gentschev I, Stritzker J, Hofmann E, et al. Use of an oncolytic vaccinia virus for the treatment of canine breast cancer in nude mice: preclinical development of a therapeutic agent. Cancer Gene Ther 2009;16:320-328.
39. Gentschev I, Ehrig K, Donat U, et al. Significant growth inhibition of canine mammary carcinoma xenografts following treatment with oncolytic vaccinia virus GLV-1h68. J Oncol 2010;2010:736907.
40. Gentschev I, Adelfinger M, Josupeit R, et al. Preclinical evaluation of oncolytic vaccinia virus for therapy of canine soft tissue sarcoma. PLoS One [serial online] 2012; 7:e37239. Available at: www.plosone.org/article/fetchObjectAttachment;jsessionid=E B9DA36616175442A5E5F9C7E105C6FD?uri=info%3Adoi%2 F10.1371%2Fjournal.pone.0037239&representation=PDF. Accessed May 15, 2012.
41. Kennedy RB, Ovsyannikova IG, Jacobson RM, et al. The immunology of smallpox vaccines. Curr Opin Immunol 2009;21:314-320.
42. Liu TC, Hwang T, Park BH, et al. The targeted oncolytic poxvirus JX-594 demonstrates antitumoral, antivascular, and anti-HBV activities in patients with hepatocellular carcinoma. Mol Ther 2008;16:1637-1642.
43. Amato RJ, Shingler W, Goonewardena M, et al. Vaccination of renal cell cancer patients with modified vaccinia Ankara delivering the tumor antigen 5T4 (TroVax) alone or administered in combination with interferon-alpha (IFN-alpha): a phase 2 trial. J Immunother 2009;32:765-772.